Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Sci Rep ; 13(1): 12985, 2023 08 10.
Article in English | MEDLINE | ID: mdl-37563292

ABSTRACT

Type 2 diabetes mellitus (T2DM) is a progressive disease, which affects colorectal cancer (CRC) survival. However, data on the relationship between CRC survival and T2DM duration is scarce and controversial. A retrospective observational study was conducted. Sub-cohorts were created based on the duration of T2DM as follows, ≤ or > 5/10/15/20 years. 204 of the 817 (24.95%) included study participants had T2DM at any point of CRC. 160 of the 204 CRC + T2DM patients had detailed T2DM duration data. At the time of CRC diagnosis, 85, 50, 31, and 11 patients had T2DM for > 5/10/15/20 years, respectively, which increased to 110, 71, 45, and 17 during the course of the study. Despite constant glycated hemoglobin values throughout the study, shorter overall and disease-specific survival times were observed for the > 5/10/15 years cohorts and longitudinal survival modeling techniques confirmed the significant effect of T2DM duration in all cohorts. While in the first 3 years after CRC diagnosis, the best survival was found for the ≤ 5 years cohort, all diabetes cohorts had the same survival thereafter. T2DM duration affected CRC survival significantly, therefore, a closer follow-up of this sub-populations is suggested.


Subject(s)
Colorectal Neoplasms , Diabetes Mellitus, Type 2 , Humans , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/diagnosis , Risk Factors , Retrospective Studies , Glycated Hemoglobin , Colorectal Neoplasms/complications , Colorectal Neoplasms/diagnosis
2.
Int J Mol Sci ; 24(14)2023 Jul 12.
Article in English | MEDLINE | ID: mdl-37511126

ABSTRACT

Pulmonary adenocarcinomas (pADCs) with an ALK rearrangement are a rare cancer subtype, necessitating comprehensive molecular investigations to unravel their heterogeneity and improve therapeutic strategies. In this pilot study, we employed spatial transcriptomic (NanoString GeoMx) and proteomic profiling to investigate seven treatment-naïve pADCs with an ALK rearrangement. On each FFPE tumor slide, 12 smaller and 2-6 larger histopathologically annotated regions were selected for transcriptomic and proteomic analysis, respectively. The correlation between proteomics and transcriptomics was modest (average Pearson's r = 0.43 at the gene level). Intertumoral heterogeneity was more pronounced than intratumoral heterogeneity, and normal adjacent tissue exhibited distinct molecular characteristics. We identified potential markers and dysregulated pathways associated with tumors, with a varying extent of immune infiltration, as well as with mucin and stroma content. Notably, some markers appeared to be specific to the ALK-driven subset of pADCs. Our data showed that within tumors, elements of the extracellular matrix, including FN1, exhibited substantial variability. Additionally, we mapped the co-localization patterns of tumor microenvironment elements. This study represents the first spatially resolved profiling of ALK-driven pADCs at both the gene and protein expression levels. Our findings may contribute to a better understanding of this cancer type prior to treatment with ALK inhibitors.


Subject(s)
Adenocarcinoma of Lung , Adenocarcinoma , Lung Neoplasms , Humans , Anaplastic Lymphoma Kinase/genetics , Anaplastic Lymphoma Kinase/metabolism , Lung Neoplasms/pathology , Receptor Protein-Tyrosine Kinases/genetics , Receptor Protein-Tyrosine Kinases/metabolism , Adenocarcinoma/pathology , Transcriptome , Pilot Projects , Proteomics , Adenocarcinoma of Lung/genetics , Adenocarcinoma of Lung/pathology , Gene Rearrangement , Tumor Microenvironment/genetics
3.
Diagnostics (Basel) ; 12(9)2022 Sep 06.
Article in English | MEDLINE | ID: mdl-36140562

ABSTRACT

In this paper, we propose a novel approach to segment tumor and normal regions in human breast tissues. Cancer is the second most common cause of death in our society; every eighth woman will be diagnosed with breast cancer in her life. Histological diagnosis is key in the process where oncotherapy is administered. Due to the time-consuming analysis and the lack of specialists alike, obtaining a timely diagnosis is often a difficult process in healthcare institutions, so there is an urgent need for improvement in diagnostics. To reduce costs and speed up the process, an automated algorithm could aid routine diagnostics. We propose an area-based annotation approach generalized by a new rule template to accurately solve high-resolution biological segmentation tasks in a time-efficient way. These algorithm and implementation rules provide an alternative solution for pathologists to make decisions as accurate as manually. This research is based on an individual database from Semmelweis University, containing 291 high-resolution, bright field microscopy breast tumor tissue images. A total of 70% of the 128 × 128-pixel resolution images (206,174 patches) were used for training a convolutional neural network to learn the features of normal and tumor tissue samples. The evaluation of the small regions results in high-resolution histopathological image segmentation; the optimal parameters were calculated on the validation dataset (29 images, 10%), considering the accuracy and time factor as well. The algorithm was tested on the test dataset (61 images, 20%), reaching a 99.10% f1 score on pixel level evaluation within 3 min on average. Besides the quantitative analyses, the system's accuracy was measured qualitatively by a histopathologist, who confirmed that the algorithm was also accurate in regions not annotated before.

4.
Genes (Basel) ; 13(4)2022 03 25.
Article in English | MEDLINE | ID: mdl-35456394

ABSTRACT

Cancer-related immunity has been identified as playing a key role in the outcome of colorectal cancer (CRC); however, the exact mechanisms are only partially understood. In this study, we evaluated a total of 242 surgical specimen of CRC patients using tissue microarrays and immunohistochemistry to evaluate tumor infiltrating immune cells (CD3, CD4, CD8, CD20, CD23, CD45 and CD56) and immune checkpoint markers (CTLA-4, PD-L1, PD-1) in systematically selected tumor regions and their corresponding lymph nodes, as well as in liver metastases. Additionally, an immune panel gene expression assay was performed on 12 primary tumors and 12 consecutive liver metastases. A higher number of natural killer cells and more mature B cells along with PD-1+ expressing cells were observed in the main tumor area as compared to metastases. A higher number of metastatic lymph nodes were associated with significantly lower B cell counts. With more advanced lymph node metastatic status, higher leukocyte-particularly T cell numbers-were observed. Eleven differentially expressed immune-related genes were found between primary tumors and liver metastases. Also, alterations of the innate immune response and the tumor necrosis factor superfamily pathways had been identified.


Subject(s)
Colorectal Neoplasms , Liver Neoplasms , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Humans , Immunohistochemistry , Liver Neoplasms/genetics , Liver Neoplasms/metabolism , Lymphocytes, Tumor-Infiltrating/metabolism , Programmed Cell Death 1 Receptor
5.
Int J Mol Sci ; 22(7)2021 Mar 30.
Article in English | MEDLINE | ID: mdl-33808426

ABSTRACT

Dietary methyl-donors play important roles in physiological processes catalyzed by B vitamins as coenzymes, and are used for complementary support in oncotherapy. Our hypothesis was that methyl-donors can not only assist in tolerating cancer treatment but may also directly interfere with tumor growth and proliferation. Therefore, we investigated the proposed cancer inhibitory effects of methyl-donors (in a mixture of L-methionine, choline chloride, folic acid, and vitamin B12) on MCF7 and T47D breast cancer as well as A549 and H1650 lung cancer cell lines. Indeed, methyl-donor treatment significantly reduced the proliferation in all cell lines, possibly through the downregulation of MAPK/ERK and AKT signaling. These were accompanied by the upregulation of the pro-apoptotic Bak and Bax, both in MCF7 and H1650 cells, at reduced anti-apoptotic Mcl-1 and Bcl-2 levels in MCF7 and H1650 cells, respectively. The treatment-induced downregulation of p-p53(Thr55) was likely to contribute to protecting the nuclear localization and apoptosis inducing functions of p53. The presented features are known to improve the sensitivity of cancer therapy. Therefore, these data support the hypothesis, i.e., that methyl-donors may promote apoptotic signaling by protecting p53 functions through downregulating both the MAPK/ERK and the AKT pathways both in breast and lung adenocarcinoma cell lines. Our results can emphasize the importance and benefits of the appropriate dietary supports in cancer treatments. However, further studies are required to confirm these effects without any adverse outcome in clinical settings.


Subject(s)
Apoptosis/physiology , MAP Kinase Signaling System/physiology , Proto-Oncogene Proteins c-akt/metabolism , Apoptosis/drug effects , Breast/pathology , Breast Neoplasms/metabolism , Cell Line, Tumor/metabolism , Cell Proliferation/drug effects , Cell Survival/drug effects , Choline/pharmacology , Folic Acid/pharmacology , Humans , Lung/pathology , Lung Neoplasms/metabolism , MAP Kinase Signaling System/drug effects , Methionine/pharmacology , Methylation/drug effects , Proto-Oncogene Proteins c-akt/drug effects , Signal Transduction/drug effects , Vitamin B 12/pharmacology
6.
Bioorg Med Chem Lett ; 30(18): 127416, 2020 09 15.
Article in English | MEDLINE | ID: mdl-32736211

ABSTRACT

Solid preclinical evidence links vasopressin to social behavior in animals, so, extensive work has been initiated to find new vasopressin V1a receptor antagonists which can improve deteriorated social behavior in humans and can treat the core symptoms of autistic behavior, as well. Our aim was to identify new chemical entities with antagonizing effects on vasopressin V1a receptors. Starting from a moderately potent HTS hit (7), we identified a molecule (49) having nanomolar binding strength and functional activity, which is in the same range as the potency of clinically tested V1a antagonists.


Subject(s)
Antidiuretic Hormone Receptor Antagonists/chemical synthesis , Receptors, Vasopressin/metabolism , Social Behavior Disorders/drug therapy , Urea/chemical synthesis , Antidiuretic Hormone Receptor Antagonists/pharmacology , High-Throughput Screening Assays , Humans , Inhibitory Concentration 50 , Piperazine/chemistry , Protein Binding , Pyridines/chemistry , Quinolines/chemistry , Structure-Activity Relationship , Urea/pharmacology
7.
Magy Onkol ; 63(4): 354-358, 2019 Dec 09.
Article in Hungarian | MEDLINE | ID: mdl-31821390

ABSTRACT

Our objective was to develop an electromagnetic tumor therapy device in a consortial cooperation between Semmelweis University and Oncotherm Ltd., to provide data and contribute to the development of the next generation of devices through preclinical, clinical and developmental modules via in vivo, in vitro studies, and patient treatments. Our numerous preclinical studies support the efficacy of mEHT. Clinical treatments were performed in 181 patients with inoperable and/or oligometastatic solid tumors. The protocols were developed, an international guideline was completed, and the planned steps of device development were realized. By optimizing previous selective RF techniques based on recent research findings, we can provide the most modern evidence-based treatment in the future.


Subject(s)
Neoplasms , Electromagnetic Phenomena , Humans
SELECTION OF CITATIONS
SEARCH DETAIL